People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Other, Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| 180 Life Sciences Corp. | — | Other | Growth/Late | $454.6M | $4.2B | 2024 |
| Atreca, Inc. | — | Biotechnology | Series D+ | $222.2M | $5.2B | 2011 |
| Tolerion, Inc. | — | Biotechnology | Series B | $43.0M | $793.8M | 2017 |
| Pasithea Therapeutics Corp. | — | Pharma | Series B | $31.8M | $591.3M | 2021 |
Lawrence Steinman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lawrence Steinman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ryan Smith | 1 | 11 |
| John Donovan | 1 | 8 |
| Franklin Berger | 1 | 7 |
| Brian Atwood | 1 | 6 |
| Paul Manning | 1 | 6 |
| Sean Stalfort | 1 | 5 |
| William Robinson | 1 | 5 |
| Blair Jordan | 1 | 3 |
| John Simpson | 1 | 3 |
| James N. Woody | 1 | 3 |
| Alexander Fleming | 1 | 2 |
| David Lacey | 1 | 2 |
| John Orwin | 1 | 2 |
| Jay Goodman | 1 | 2 |
| Tito Serafini | 1 | 2 |
| James Stutz | 1 | 2 |
| Stephen Zachary | 1 | 2 |
| Stephen Shoemaker | 1 | 2 |
| McAndrew Rudisill | 1 | 1 |
| Eric Van Lent | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.